

***Remarks***

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 41-167 are pending in the application, with claims 41, 80, 96, 110, and 133 being the independent claims. Claims 1-40 have been cancelled without prejudice to or disclaimer of the subject matter therein. Claims 41-167 have been added.

Support for newly added claims 41-167 can be found throughout the specification. For the Examiner's convenience, **Table 1** (attached) sets out examples of locations where support for the new claims can be found in the present application and the priority applications.

The specification has also been amended to perfect the claim for benefit of earlier applications. As this application was filed before November 29, 2000, the amendment of the claim for benefit is timely. 37 C.F.R. § 1.78 (a)(2)(ii)(C). MPEP § 201.11(E). Support for the incorporation by reference of the priority applications may be found in the original specification in the paragraph beginning at page 1, line 9.

The specification has been amended in the paragraph beginning at page 12, line 25 to state that CTL-inducing peptides of the invention can be less than about 15 residues in length. Support for this amendment can be found in priority Appl. No. 09/098,584 at page 5, lines 2-3, in priority Appl. No. 09/017,735 at page 3, lines 23-25, and in priority Appl. No. 08/589,108 at page 3, lines 21-23. These applications were originally incorporated by reference into the present application.

The specification has been amended to insert the Substitute Sequence Listing, submitted herewith, which has been changed to reflect the current priority claim. In

accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above-captioned application are the same. In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

It is believed that these changes introduce no new matter, and their entry is respectfully requested.

New claims 41, 43, 51-53, and 65-79 read on the peptide elected in Applicant's Reply to Restriction Requirement filed on December 2, 2003.

Applicants have organized the independent claims to include peptides having the same priority dates to aid in examination. Thus, Applicants request examination of a reasonable number of peptides, notwithstanding the fact that they are recited in several independent claims. Applicants note that, to the best of Applicants' knowledge, the peptides recited in claims 41-48 were first disclosed in Appl. No. 08/589,108, filed January 23, 1996, the peptides recited in claims 110-112 were first disclosed in Appl. No. 09/017,735, filed February 3, 1998, and the peptides recited in claims 133-138 were first disclosed in Appl. No. 09/098,584, filed June 17, 1998.

The peptide recited in claims 80 and 96 was first disclosed in Appl. No. 09/016,361, filed January 30, 1998. This peptide was also disclosed in Appl. No. 09/017,735, filed February 3, 1998. Support for claims 80-95 can be found in Appl. No. 09/017,735; support for claims 96-109 can be found in Appl. No. 09/016,361.

It is believed that the application is now in condition for examination. Early notice to this effect is respectfully requested.

***Conclusion***

Consideration of this Amendment is respectfully requested. Applicants respectfully submit that the application is in proper condition for allowance.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson  
Agent for Applicants  
Registration No. 47,473

Date: 2/18/2004

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



**Table 1- Example of Support for Claims**

<u>Claim Language</u>	<u>This Application</u>	<u>08/589,108</u>	<u>09/017,735</u>	<u>09/016,361</u>	<u>09/098,584</u>
T helper peptide	p. 50, line 17-through p.51, line 22	p. 15, lines 4-23	p.15, lines 6-22		p.16, lines 16-20
Spacer or linker	p.50, lines 22-30	p. 15, lines 8-19	p.15, lines 8-16		p. 16, lines 7-17
Carrier	p. 42, lines 28-30; p. 55, lines 12-16	p. 19, lines 6-10; p. 21, lines 3-4	p. 21, lines 6-7	p. 24, lines 19-24; p. 26, lines 4-12	p. 21, lines 23-24
Lipid	p. 51, line 25 through p. 52, line 15	p. 15, lines 23 through p. 16, line 6	p. 16, lines 3-11		p. 16, lines 22-30
Fusion protein	p. 38, lines 12-18	p. 17, lines 7-13	p. 17, lines 3-4	p. 16, lines 31-32	p. 17, lines 29-30
Liposome	p. 56, line 1-17	p. 19, line 24 through p. 20, line 8	p. 19, line 26 through p. 20, line 11	p. 25, lines 4-21	p. 20, lines 14-30
Homopolymer/heteropolymer	p. 42, lines 28-30	p. 21, lines 3-4	p. 21, lines 6-7	p. 26, lines 4-6	p. 21, lines 23-24
Less than about 15 residues in length	p. 12, lines 28-30, as amended herewith	p. 3, lines 21-23	p. 3, lines 23-25		p. 5, lines 2-3
8, 9, 10, or 11 residues	p. 12, lines 28-30	p. 3, lines 21-23	p. 3, lines 23-25		p. 5, lines 2-3
9 or 10 amino acid residues				p. 16, lines 2-5	